Form4insider filings, from the source

SEC Form 4 · accession 0001209191-17-038521

AGIOS PHARMACEUTICALS, INC. · AGIO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
David P Schenkein
Officer — Chief Executive Officer · Director
Period of report
Jun 6, 2017
Accepted (ET)
Jun 8, 2017 · 4:06 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001439222

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common stockJun 6, 2017M1,100$0.3025A1,100D
Common stockF3Jun 6, 2017S1,100$50.02D0D
Common stockJun 7, 2017M1,900$0.3025A1,900D
Common stockF4Jun 7, 2017S1,900$50.02D0D
Common stockF5holding———272,272ISee footnote
Common stockF6holding———79,082ISee footnote

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock option (right to buy)F7$0.3025Jun 6, 2017M1,100D—Aug 12, 2019Common stock1,100191,556D
Stock option (right to buy)F7$0.3025Jun 7, 2017M1,900D—Aug 12, 2019Common stock1,900189,656D

Explanation of responses